Hematology/Oncology · Sylmar, CA
NPI
1174726954
Since 2007
Specialty
Hematology/Oncology
Code 174400000X
Group practices
3
Medicare group memberships
Hospitals
1
Hospital affiliations
14445 Olive View Dr, Room 2b-182
Sylmar, CA, 91342
Phone (818) 364-3205
Groups this clinician bills Medicare through
Medicare paid
-
No Medicare services published
Medicare patients
-
Drug cost, 2024
$4.6M
1,320 prescriptions
Company payments
-
None reported
Medicare prescription drug claims, 2024
In 2024, the drug Roslyn M Chaisanguanthum prescribed most often to Medicare patients was Letrozole, with 256 prescriptions and refills. In total Roslyn M Chaisanguanthum wrote 1,320 Medicare prescriptions that cost $4.6M.
| Drug |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-09-23.
| Claims |
|---|
| 30-day fills |
|---|
| Patients |
|---|
| Cost |
|---|
| Letrozole Generic | 256 | 764 | 88 | $5,233 |
| Dexamethasone Generic | 122 | 122 | 33 | $1,592 |
| Anastrozole Generic | 65 | 196 | 24 | $1,826 |
| Abiraterone Acetate Generic | 59 | 59 | Under 11 | $8,844 |
| Potassium Chloride Generic | 43 | 92 | 17 | $1,576 |
| Lenalidomide Generic | 42 | 42 | Under 11 | $433K |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 40 | 40 | Under 11 | $1,535 |
| Prednisone Generic | 39 | 40 | Under 11 | $268 |
| Ibrance Palbociclib | 36 | 36 | Under 11 | $555K |
| Tagrisso Osimertinib Mesylate | 33 | 33 | Under 11 | $568K |
| Olanzapine Generic | 31 | 35 | 21 | $195 |
| Prochlorperazine Maleate Generic | 29 | 29 | 27 | $477 |
| Calquence Acalabrutinib Maleate | 27 | 27 | Under 11 | $374K |
| Exemestane Generic | 23 | 69 | Under 11 | $2,359 |
| Nivestym Filgrastim-Aafi | 23 | 23 | Under 11 | $15K |
Brand drugs: - claims; generic drugs: 994 claims; opioid claims: 45.
Money and other things of value reported by the companies
No payments from drug or medical device companies to Roslyn M Chaisanguanthum were reported in the years we have.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.